Lead Investigator: Georgia Salanti, University of Bern
Title of Proposal Research: Making real world predictions for clinical outcomes in Relapsing-Remitting Multiple Sclerosis
Vivli Data Request: 5948
Funding Source: None
Potential Conflicts of Interest: None
Summary of the Proposed Research:
Multiple Sclerosis (MS) is a chronic disease of young adults, affecting approximately 15000 patients in Switzerland. While the disease has only minor impact on life expectancy, its long duration (mean of 30-40 years) and the fact that it leads to significant disability results in a very important socio-economic impact.
Although progress has been made in understanding disease pathogenesis, and partially effective treatment are available, many questions remain unanswered. The development and validation of diagnostic and prognostic markers of spontaneous disease evolution and therapeutic response can help to improve patient care and possibly allows to establish individualized therapy approaches.
Requested Studies:
A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
Sponsor: Biogen
Study ID: NCT01332019
Sponsor ID: 105MS302
Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) Versus Avonex® (Interferon β 1a) in Patients With Relapsing-Remitting Multiple Sclerosis
Sponsor: Biogen
Study ID: NCT01064401
Sponsor ID: 205MS301
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab in Subjects With Relapsing-Remitting Multiple Sclerosis
Sponsor: Biogen
Study ID: NCT00027300
Sponsor ID: C-1801
Update: This data request was withdrawn on 21 December 2021 by the researcher.